Nabriva Therapeutics plc Annual Income Tax Expense (Benefit) in USD from 2014 to 2022

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Nabriva Therapeutics plc quarterly/annual Income Tax Expense (Benefit) history and growth rate from 2014 to 2022.
  • Nabriva Therapeutics plc Income Tax Expense (Benefit) for the quarter ending June 30, 2023 was $0.000, a 100% decline year-over-year.
  • Nabriva Therapeutics plc annual Income Tax Expense (Benefit) for 2022 was $1.57M, a 220% increase from 2021.
  • Nabriva Therapeutics plc annual Income Tax Expense (Benefit) for 2021 was $490K, a 253% increase from 2020.
  • Nabriva Therapeutics plc annual Income Tax Expense (Benefit) for 2020 was $139K, a 37.6% increase from 2019.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2022 $1.57M +$1.08M +220% Jan 1, 2022 Dec 31, 2022 10-K 2023-04-17
2021 $490K +$351K +253% Jan 1, 2021 Dec 31, 2021 10-K 2023-04-17
2020 $139K +$38K +37.6% Jan 1, 2020 Dec 31, 2020 10-K 2023-04-17
2019 $101K +$52K +106% Jan 1, 2019 Dec 31, 2019 10-K 2022-03-29
2018 $49K -$1.31M -96.4% Jan 1, 2018 Dec 31, 2018 10-K 2021-03-11
2017 $1.36M +$2.03M Jan 1, 2017 Dec 31, 2017 10-K 2020-03-12
2016 -$672K -$227K -51% Jan 1, 2016 Dec 31, 2016 10-K 2019-03-12
2015 -$445K -$539K -573% Jan 1, 2015 Dec 31, 2015 10-K 2018-03-16
2014 $94K Jan 1, 2014 Dec 31, 2014 10-K 2017-03-24
* An asterisk sign (*) next to the value indicates that the value is likely invalid.